Kidney Architecture Changes in a MASH High-Fat Diet Ob/Ob Mouse Model: Protection by FXR Agonists OCA and INT-787
Metabolic dysfunction-associated steatohepatitis (MASH) frequently induces renal injury, and current therapies primarily target hepatic lesions. In this work, we examined liver-induced kidney alterations in an ob/ob mouse model of MASH also through in situ autofluorescence (AF) imaging of renal tissue, and the effects of FXR agonists, Obeticholic acid (OCA) and INT-787. Lep ob/ob mice with diet-induced MASH received either a high-fat diet (HFD) or control diet (CD) for 9 weeks (wks), followed by treatment with OCA or INT-787 (0.05% mixed into HFD; 30 mg/kg/day) for an additional 12 wks. Serum ALT, bilirubin, bile acids, cholesterol, creatinine and urea were measured. Renal MMP-2 and MMP-9 activities were quantified as well as AF images and collagen fiber orientation. HFD-fed mice developed marked liver dysfunction without biochemical evidence of kidney injury, as indicated by stable serum renal markers. No significant differences were detected in MMP activities across groups. AF scattered-light imaging revealed a clear disruption of the fibrillar collagen network: quantitative analysis of collagen fiber orientation showed that HFD 21-wk kidneys exhibited a substantial increase in fiber misalignment. Treatment with INT-787 or OCA significantly reduced angular dispersion, preserving collagen organization to values comparable to CD mice. AF imaging proved highly informative, serving not only to enhance structural visualization but also as an early indicator of kidney alterations. Given that collagen fiber orientation reflects underlying fibrotic remodeling, our findings demonstrate that diet-induced MASH compromises renal tissue architecture, and that FXR agonists effectively counteract these early structural abnormalities.
Authors
- Stefano Perlini (ORCID: https://orcid.org/0000-0002-0320-8574)
- Gloria Milanesi (ORCID: https://orcid.org/0000-0002-0454-1416)
- Margherita Cavallo (ORCID: https://orcid.org/0009-0005-7071-1996)
- Laura Giuseppina Di Pasqua (ORCID: https://orcid.org/0000-0003-0103-1493)
- Andrea Ferrigno (ORCID: https://orcid.org/0000-0003-2337-2897)
- Mariapia Vairetti (ORCID: https://orcid.org/0000-0002-2464-6127)
- Luciano Adorini (ORCID: https://orcid.org/0000-0001-8109-339X)
- Giuseppina Palladini (ORCID: https://orcid.org/0000-0003-1312-7513)
- Anna Cleta Croce (ORCID: https://orcid.org/0000-0001-8996-2895)
Institutions
- University of Pavia (IT)
- Istituto di Genetica Molecolare (IT)
- Policlinico San Matteo Fondazione (IT)
- National Research Council (IT)
- Intercept Pharmaceuticals (United States) (US)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3390/ijms272210369
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Università degli Studi di Pavia